Cart
sales@molnova.com
5-Amino-5-deoxyadenosine
CAS No. 14365-44-7
5-Amino-5-deoxyadenosine( —— )
Catalog No. M33704 CAS No. 14365-44-7
5'-Amino-5'-deoxyadenosine (NH2dAdo) is an adenosine kinase inhibitor targeting malignant tumors of the inert lymphatic system with antitumor and anticancer effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 103 | In Stock |
|
| 10MG | 170 | In Stock |
|
| 25MG | 280 | In Stock |
|
| 50MG | 418 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name5-Amino-5-deoxyadenosine
-
NoteResearch use only, not for human use.
-
Brief Description5'-Amino-5'-deoxyadenosine (NH2dAdo) is an adenosine kinase inhibitor targeting malignant tumors of the inert lymphatic system with antitumor and anticancer effects.
-
Description5'-Amino-5'-deoxyadenosine (NH2dAdo; Nsc 238990) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis | Adenosine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number14365-44-7
-
Formula Weight266.26
-
Molecular FormulaC10H14N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 200 mg/mL (751.15 mM; Ultrasonic )
-
SMILESO[C@H]1[C@H](N2C=3C(N=C2)=C(N)N=CN3)O[C@H](CN)[C@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.?
molnova catalog
related products
-
Se-Aspirin
Se-Aspirin (Se-NSAID-8) has anticancer activity and gastroprotective effects, inhibits activation of proinflammatory and pro-survival NF-?B pathways, and inhibits the expression of anti-apoptotic targets downstream of NF-?B (e.g., Bcl-xL, Mcl-1, and survivin).
-
Simmiparib
Simmiparib (SMOCL-9112) is a novel and potent PARP1 and PARP2 inhibitor, a derivative of Olaparib.
-
Eriocalyxin B
Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways, should be considered a candidate for pancreatic cancer treatment.
